CYTOIMMUNE THERAPEUTICS
CytoImmune Therapeutics develops novel, coordinated immunotherapy solutions for patients. Their CoalesceNT platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.
CYTOIMMUNE THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2019-01-01
Address:
Monrovia, California, United States
Country:
United States
Website Url:
http://www.cytoimmune.com
Total Employee:
51+
Status:
Active
Contact:
4692222350
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API WordPress Font Awesome Apache Wordpress Plugins Microsoft Exchange Online
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2021-06-24 | CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer |
Official Site Inspections
http://www.cytoimmune.com Semrush global rank: 5.05 M Semrush visits lastest month: 1.64 K
- Host name: 104.21.23.36
- IP address: 104.21.23.36
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "CytoImmune Therapeutics"
About Us - cytoimmune
CytoImmune’s integrated ecosystem of biologic and cell therapy technologies and capabilities enables us to discover, develop, manufacture, and commercialize an unprecedented, broad …See details»
CytoImmune Therapeutics - Crunchbase Company …
Jul 2, 2020 CytoImmune Therapeutics develops novel, coordinated immunotherapy solutions for patients. Their CoalesceNT platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) …See details»
Investors & Media - cytoimmune
Apr 11, 2022 City of Hope and CytoImmune announce study demonstrating novel off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell-based therapy against pancreatic cancer. December 14, 2021. CytoImmune …See details»
CytoImmune Therapeutics - LinkedIn
CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients. Our CoalesceNTâ„¢ platform harnesses the power of bispecific antibody (biAb) and chimeric antigen ...See details»
CytoImmune Therapeutics - Overview, News & Similar companies
Mar 1, 2023 Who is CytoImmune Therapeutics. CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel …See details»
City of Hope enters licensing agreements with CytoImmune …
Duarte and Monrovia, Calif. – City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and CytoImmune …See details»
CytoImmune Therapeutics, Inc. Opens the Company’s …
Mar 24, 2022 CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the ...See details»
CytoImmune Therapeutics and City of Hope Announce First …
Jul 28, 2022 About CytoImmune CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy …See details»
Our Science - cytoimmune
CytoImmune Operates a Fully Integrated CAR-NK Manufacturing Facility. In-house clinical GMP manufacturing facility for cells and virus with compelling operating economics. In-house Manufacturing in Puerto Rico. 37,000 ft2 …See details»
Matica Bio and CytoImmune Establish a Strategic Partnership
Oct 9, 2024 COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in …See details»
CytoImmune Therapeutics Appoints Renowned Oncologist and …
Nov 10, 2021 About CytoImmune Therapeutics, Inc. Founded in 2017, CytoImmune Therapeutics is a clinical-stage biotechnology company, focused on developing an innovative …See details»
CytoImmune to Present New Preclinical Data Highlighting …
Mar 8, 2022 About CytoImmune CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy …See details»
CytoImmune Therapeutics Announces Publication Demonstrating
Jan 25, 2022 The study, which took place at City of Hope, a world-renowned cancer research and treatment organization, found that PDGF-D activates NK cells via its receptor, PDGFRβ, …See details»
CytoImmune Presents New Preclinical Data Demonstrating …
Apr 11, 2022 About CytoImmune CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel …See details»
Matica Bio and CytoImmune Establish a Strategic Partnership for …
News. Matica Bio and CytoImmune Establish a Strategic Partnership for Cell Therapy Development and Manufacturing October 9, 2024See details»
City of Hope and CytoImmune announce study ... - Business Wire
Jan 18, 2022 DUARTE, Calif. & TOA BAJA, Puerto Rico--(BUSINESS WIRE)--City of Hope, a world-renowned cancer research and treatment organization, and CytoImmune Therapeutics, …See details»
CytoImmune Presents New Preclinical Data Demonstrating …
Apr 11, 2022 CytoImmune Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed …See details»
CytoImmune – CellCore Biosciences
CytoImmune is the perfect immune supplement to have on hand before you need it. A well-rounded, ideal solution for a healthy immune and inflammatory response year-round, …See details»
Our Pipeline - cytoimmune
CytoImmune Therapeutics is a clinical-stage biotechnology company, developing a novel class of cancer immunotherapy medicines based on engineered, allogeneic, tumor-reactive natural …See details»